Swissmedic grants authorisation for a paediatric antimalarial under the Marketing Authorisation for Global Health Products (MAGHP) procedure
Bern, 08.07.2025 — Swissmedic has authorised a novel paediatric formulation of an antimalarial medicine: Riamet Baby (Coartem Baby), specifically developed for infants with a bodyweight between 2 kg and 5 kg. This marks a significant step in the global effort to improve access to life-saving treatments for vulnerable populations. It is the third authorisation granted under the MAGHP procedure and underscores the value of international collaboration in addressing urgent public health needs.